Citius Oncology Elects Three Directors Through 2029

Stockholders ratified Wolf & Company, P.C. for the fiscal year ended September 30, 2026, with 73,533,649 votes for and 8,809,478 against.

Rhea-AI Filing Summary

Citius Oncology, Inc. (CTOR) stockholders elected Dr. Eugene Holuka, Robert Smith and Carol Webb as Class II directors for three-year terms expiring at the 2029 annual meeting, or until successors are duly elected and qualified. Holuka received 67,835,202 votes for and 8,267,153 withheld; Smith received 67,883,403 for and 8,218,952 withheld; Webb received 67,895,374 for and 8,206,981 withheld. Each nominee had 6,255,142 broker non-votes.

Stockholders also ratified Wolf & Company, P.C. as independent registered public accounting firm for the fiscal year ended September 30, 2026: 73,533,649 votes for, 8,809,478 against, 14,370 abstentions and no broker non-votes.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Dr. Eugene Holuka votes for: 67,835,202 votes Robert Smith votes for: 67,883,403 votes Carol Webb votes for: 67,895,374 votes +4 more

7 metrics

Dr. Eugene Holuka votes for 67,835,202 votes 2026 annual meeting director election

Robert Smith votes for 67,883,403 votes 2026 annual meeting director election

Carol Webb votes for 67,895,374 votes 2026 annual meeting director election

Broker non-votes per director nominee 6,255,142 votes 2026 annual meeting director election

Auditor ratification votes for 73,533,649 votes Fiscal year ended September 30, 2026

Auditor ratification votes against 8,809,478 votes Fiscal year ended September 30, 2026

Auditor ratification abstentions 14,370 abstentions Fiscal year ended September 30, 2026

Key Terms

Class II directors, Withheld, Broker Non-Votes, independent registered public accounting firm

4 terms

Class II directors regulatory

"elected the following Class II directors"

Withheld regulatory

"For | Withheld | Broker Non-Votes"

Broker Non-Votes regulatory

"For | Withheld | Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm regulatory

"ratified the selection of Wolf & Company, P.C. as our independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which directors did CTOR stockholders elect at the 2026 annual meeting?

Stockholders elected Dr. Eugene Holuka, Robert Smith and Carol Webb as Class II directors. Each has a three-year term expiring at the 2029 annual meeting, or until a successor is duly elected and qualified. The nominees received 67,835,202, 67,883,403 and 67,895,374 votes for, respectively.

What was the vote on CTOR’s auditor for fiscal 2026?

Stockholders ratified Wolf & Company, P.C. as independent registered public accounting firm for the fiscal year ended September 30, 2026. The vote was 73,533,649 for, 8,809,478 against and 14,370 abstentions, with no broker non-votes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/29/2026 - 04:31 PM Accepted by SEC EDGAR 09/29/2026 - 04:30 PM Learn about SEC filing dates

false 0001851484 0001851484 2026-09-29 2026-09-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 29, 2026

Citius Oncology, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-41534		99-4362660
(Commission File Number)		(IRS Employer Identification No.)

11 Commerce Drive, 1st Floor, Cranford, NJ		07016
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (908) 967-6677

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		CTOR		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

On September 29, 2026, Citius Oncology, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, our stockholders elected the following Class II directors for a three-year term expiring at the annual meeting of stockholders to be held in 2029 or until their successors are duly elected and qualified, based on the following votes:

Nominee		For		Withheld		Broker Non-Votes
Dr. Eugene Holuka		67,835,202		8,267,153		6,255,142
Robert Smith		67,883,403		8,218,952		6,255,142
Carol Webb		67,895,374		8,206,981		6,255,142

Next, our stockholders ratified the selection of Wolf & Company, P.C. as our independent registered public accounting firm for the fiscal year ended September 30, 2026. The vote for such ratification was 73,533,649 shares for, 8,809,478 shares against, 14,370 shares abstaining, and no broker non-votes.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 29, 2026	CITIUS ONCOLOGY, INC.
	By:	/s/ Leonard Mazur
		Leonard Mazur
		Chairman and Chief Executive Officer

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB